# ANVIL (NCT02595944)

> Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02595944
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Interventions: Biospecimen Collection; Computed Tomography; Echocardiography Test; Nivolumab; Observation Activity; Positron Emission Tomography
- Enrollment: 903
- Primary outcome: Disease-free survival (DFS)
- Primary outcome: Overall survival (OS)

## Commentary we found

- X threads: 11
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=anvil-nct02595944

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02595944", "email": "<work email>"}; the inbox owner confirms by the emailed link.